株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシーの世界市場の分析・予測

Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies

発行 Renub Research 商品コード 686993
出版日 ページ情報 英文 138 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
リキッドバイオプシーの世界市場の分析・予測 Liquid Biopsy Market, Global Analysis by Cancer (Lung, Breast, Colorectal), Products, Circulating Biomarkers, Sample, Clinical Application, Regions & Companies
出版日: 2018年08月01日 ページ情報: 英文 138 Pages
概要

リキッドバイオプシーの市場は世界的な癌有病率の増加、最小侵襲性技術への認知度の拡大などの影響から、2024年には34億米ドルを超える規模に成長すると予測されています。

当レポートでは、世界のリキッドバイオプシーの市場を調査し、市場規模の推移と予測、癌区分・製品区分・循環バイオマーカー区分・サンプル・臨床用途・地域・企業別の内訳、市場成長への影響因子および課題の分析、主要企業の分析などをまとめています。

第1章 エグゼクティブサマリー

第2章 世界市場の分析:リキッドバイオプシー

第3章 市場シェア:リキッドバイオプシー

第4章 リキッドバイオプシー市場の分析・予測:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第5章 リキッドバイオプシー市場の分析・予測:癌区分別

  • 肺癌
  • 乳癌
  • 大腸癌
  • 前立腺癌
  • その他

第6章 リキッドバイオプシー市場の分析・予測:製品別

  • キット・消耗品
  • 機器
  • サービス

第7章 リキッドバイオプシー市場の分析・予測:循環バイオマーカー別

  • 循環腫瘍細胞 (CTC)
  • 血中循環腫瘍DNA (ctDNA)
  • エキソソーム

第8章 リキッドバイオプシー市場の分析・予測:臨床用途別

  • モニタリング
  • 予後
  • セラノスティクス
  • スクリーニング

第9章 リキッドバイオプシー市場の分析・予測:サンプル別

  • 血漿・血清
  • 尿
  • その他

第10章 企業分析:Thermo Fisher Scientific Inc

  • 製品ポートフォリオ
  • 財務分析

第11章 企業分析:Roche Diagnostics

  • 製品ポートフォリオ
  • 財務分析

第12章 企業分析:Bio-Rad Laboratories Inc

  • 製品ポートフォリオ
  • 財務分析

第13章 企業分析:Biocept, Inc.

  • 製品ポートフォリオ
  • 財務分析

第14章 企業分析:Biocartis

  • 製品ポートフォリオ
  • 財務分析

第15章 企業分析:Myriad Genetics, Inc

  • 製品ポートフォリオ
  • 財務分析

第16章 企業分析:Genomic Health

  • 製品ポートフォリオ
  • 財務分析

第17章 企業分析:NeoGenomics Laboratories

  • 製品ポートフォリオ
  • 財務分析

第18章 企業分析:Qiagen

  • 製品ポートフォリオ
  • 財務分析

第19章 成長推進因子

  • リアルタイム評価・利便性・精度
  • 最小侵襲型生検技法への需要増
  • 技術の進歩・パーソナライズド医療

第20章 課題

  • リキッドバイオプシーの障壁
  • 償還の不明確性・限定性と高コスト性
目次

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024 , witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient's tumor and provide clues about the treatment that a patient's needs.

Renub Research report titled "Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen) " provides a complete analysis of Global Liquid Biopsy Market.

By Cancer - Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

image1

By Product - Majority of Liquid Biopsy Market held by Kits & Consumables

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

By Circulating Biomarkers

The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample - Plasma/Serum accounts for the maximum market

In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application - Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region - North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

All the 9 Companies Studied in the Report have been Studied from 3 Points

  • Company Overview
  • Product Portfolio
  • Financial Insight

This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years.

By Cancer

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By Product

  • Kits & Consumables
  • Instruments
  • Services

By Circulating Biomarkers

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Exosomes

By Sample

  • Plasma/Serum
  • Urine
  • Others

By Clinical Application

  • Monitoring
  • Prognosis
  • Theranostics
  • Screening

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East/Africa

By Companies

  • Thermo Fisher Scientific Inc.
  • Roche Diagnostics
  • Bio-Rad Laboratories Inc.
  • Biocept Inc.
  • Biocartis
  • Myriad Genetics, Inc.
  • Genomic Health
  • NeoGenomics Laboratories
  • Qiagen

Table of Contents

1. Executive Summary

2. Global - Liquid Biopsy Market

3. Market Share - Global Liquid Biopsy

  • 3.1 By Region
  • 3.2 By Cancer
  • 3.3 By Product
  • 3.4 By Circulating Biomarkers

4. Region - Liquid Biopsy Market

  • 4.1 North America
  • 4.2 Europe
  • 4.3 Asia-Pacific
  • 4.4 Latin America
  • 4.5 Middle East & Africa

5. Cancer - Liquid Biopsy Market

  • 5.1 Lung Cancer
  • 5.2 Breast Cancer
  • 5.3 Colorectal Cancer
  • 5.4 Prostate Cancer
  • 5.5 Others

6. By Product - Liquid Biopsy Market

  • 6.1 Kits & Consumables
  • 6.2 Instruments
  • 6.3 Services

7. Circulating Biomarkers - Liquid Biopsy Market

  • 7.1 Circulating Tumor Cells (CTCs)
  • 7.2 Circulating Tumor DNA (ctDNA)
  • 7.3 Exosomes

8. By Clinical Application - Liquid Biopsy Market

  • 8.1 Monitoring
  • 8.2 Prognosis
  • 8.3 Theranostics
  • 8.4 Screening

9. By Sample - Liquid Biopsy Market

  • 9.1 Plasma / Serum
  • 9.2 Urine
  • 9.3 Others

10. Thermo Fisher Scientific Inc - Company Analysis

  • 10.1 Product Portfolio
    • 10.1.1 Financial Insight

11 Roche Diagnostics - Company Analysis

  • 11.1 Product Portfolio
    • 11.1.1 Financial Insight

12. Bio-Rad Laboratories Inc - Company Analysis

  • 12.1 Product Portfolio
    • 12.1.1 Financial Insight

13. Biocept, Inc. - Company Analysis

  • 13.1 Product Portfolio
  • 13.2 Financial Insight

14. Biocartis - Company Analysis

  • 14.1 Product Portfolio
  • 14.2 Financial Insight

15. Myriad Genetics, Inc - Company Analysis

  • 15.1 Product Portfolio
  • 15.2 Financial Insight

16. Genomic Health - Company Analysis

  • 16.1 Product Portfolio
  • 16.2 Financial Insight

17. NeoGenomics Laboratories - Company Analysis

  • 17.1 Product Portfolio
  • 17.2 Financial Insight

18. Qiagen - Company Analysis

  • 18.1 Product Portfolio
  • 18.2 Financial Insight

19. Growth Drivers

  • 19.1 Real-Time Evaluation, Convenient and Accuracy
  • 19.2 Increasing Demand for Minimally-Invasive Biopsy Techniques
  • 19.3 Technical Advancement & Personalized Therapies

20. Challenges

  • 20.1 Barriers for Liquid Biopsies
  • 20.2 High Cost with Uncertain or Limited Reimbursement for Liquid Biopsy

List of Figures:

  • Figure 2-1: Global - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 2-2: Global - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 3-1: By Region - Liquid Biopsy Market Share (%), 2013 - 2017
  • Figure 3-2: By Region - Forecast for Liquid Biopsy Market Share (%), 2018 - 2024
  • Figure 3-3: By Cancer - Liquid Biopsy Market Share (%), 2013 - 2017
  • Figure 3-4: By Cancer - Forecast for Liquid Biopsy Market Share (%), 2018 - 2024
  • Figure 3-5: By Product - Liquid Biopsy Market Share (%), 2013 - 2017
  • Figure 3-6: By Product - Forecast for Liquid Biopsy Market Share (%), 2018 - 2024
  • Figure 3-7: By Circulating Biomarkers - Liquid Biopsy Market Share (%), 2013 - 2017
  • Figure 3-8: By Circulating Biomarkers - Forecast for Liquid Biopsy Market Share (%), 2018 - 2024
  • Figure 4-1: United State Cancers by rates of New Cancer Cases (Male & Female) - 2015
  • Figure 4-2: United State Cancers by rates of Cancer Deaths (Male & Female) - 2015
  • Figure 4-3: North America - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 4-4: North America - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 4-5: Europe - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 4-6: Europe - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 4-7: Asia-Pacific - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 4-8: Asia-Pacific - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 4-9: Latin America - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 4-10: Latin America - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 4-11: Middle East & Africa - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 4-12: Middle East & Africa - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 5-1: Lung Cancer - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 5-2: Lung Cancer - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 5-3: Breast Cancer - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 5-4: Breast Cancer - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 5-5: Colorectal Cancer - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 5-6: Colorectal Cancer - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 5-7: Prostate Cancer - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 5-8: Prostate Cancer - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 5-9: Others - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 5-10: Others - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 6-1: Kits & Consumables - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 6-2: Kits & Consumables - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 6-3: Instruments - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 6-4: Instruments - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 6-5: Services - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 6-6: Services - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 7-1: CTCs - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 7-2: CTCs - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 7-3: ctDNA - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 7-4: ctDNA - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 7-5: Exosomes - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 7-6: Exosomes - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 8-1: Monitoring - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 8-2: Monitoring - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 8-3: Prognosis - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 8-4: Prognosis - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 8-5: Theranostics - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 8-6: Theranostics - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 8-7: Screening - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 8-8: Screening - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 9-1: Plasma/Serum - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 9-2: Plasma/Serum - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 9-3: Urine - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 9-4: Urine - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 9-5: Others - Liquid Biopsy Market (Million US$), 2013 - 2017
  • Figure 9-6: Others - Forecast for Liquid Biopsy Market (Million US$), 2018 - 2024
  • Figure 10-1: Thermo Fisher - Diagnostics Sales (Million US$), 2013 - 2017
  • Figure 10-2: Thermo Fisher - Forecast for Diagnostics Sales (Million US$), 2018 - 2024
  • Figure 11-1: Roche Diagnostics - Diagnostics Sales (Billion US$), 2013 - 2017
  • Figure 11-2: Roche Diagnostics - Forecast for Diagnostics Sales (Billion US$), 2018 - 2024
  • Figure 12-1: Bio-Rad Laboratories - Net Sales (Million US$), 2013 - 2017
  • Figure 12-2: Bio-Rad Laboratories - Forecast for Net Sales (Million US$), 2018 - 2024
  • Figure 13-1: Biocept - Revenue (Million US$), 2013 - 2017
  • Figure 13-2: Biocept - Forecast for Revenue (Million US$), 2018 - 2024
  • Figure 14-1: Biocartis - Net Sales (Thousand US$), 2013 - 2017
  • Figure 14-2: Biocartis - Forecast for Net Sales (Thousand US$), 2018 - 2024
  • Figure 15-1: Myriad Genetics - Molecular Diagnostics Revenue (Million US$), 2013 - 2017
  • Figure 15-2: Myriad Genetics - Forecast for Molecular Diagnostics Revenue (Million US$), 2018 - 2024
  • Figure 16-1: Genomic Health - Net Sales (Million US$), 2013 - 2017
  • Figure 16-2: Genomic Health - Forecast for Net Sales (Million US$), 2018 - 2024
  • Figure 17-1: NeoGenomics Laboratories - Net Sales (Million US$), 2013 - 2017
  • Figure 17-2: NeoGenomics Laboratories - Forecast for Net Sales (Million US$), 2018 - 2024
  • Figure 18-1: Qiagen - Revenue (Million US$), 2013 - 2017
  • Figure 18-2: Qiagen - Forecast For Revenue (Million US$), 2018 - 2024

List of Tables:

  • Table 4-1: Estimated number of people living with cancer: by nation, at the end of 2010, 2015, 2020 and 2030
  • Table 4-2: Cancer Statistics Japan - 2017
Back to Top